Exelixis Email Format
Biotechnology Research
・
1,001-2,500 employees
・
Alameda, CA, USA
Exelixis is a biotechnology company focused on discovering, developing, and commercializing innovative cancer treatments to improve outcomes for patients worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@exelixis.com
Company Overview
Industry
Biotechnology Research
Founded
1994
Headquarters
Alameda, CA, USA
Revenue
$1B-$2.5B
FUNDING Stage
Public
Website
Key Executives
Michael M. Morrissey, Ph.D. (President and Chief Executive Officer), Christopher J. Senner (Executive Vice President and Chief Financial Officer), P.J. Haley (Executive Vice President, Commercial)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Exelixis?
Exelixis uses the firstinitiallast format, so Jane Smith would be jsmith@exelixis.com.
What cancer types is Exelixis' flagship product CABOMETYX approved to treat?
CABOMETYX is FDA-approved for advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, and previously treated pancreatic and extrapancreatic neuroendocrine tumors. You can verify current approval status for specific Exelixis contacts using a tool like Clay to enrich and target the right teams.
Where is Exelixis headquartered and who leads the company?
Exelixis is headquartered in Alameda, California, and is led by President and Chief Executive Officer Michael M. Morrissey, Ph.D., who has held the role since July 2010.
How far along is Exelixis' zanzalintinib program for metastatic colorectal cancer?
The FDA accepted Exelixis' NDA for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer in February 2026, based on the phase 3 STELLAR-303 trial, with a PDUFA target action date of December 3, 2026.
Does Exelixis have international partnerships for commercializing its cabozantinib franchise?
Yes, Exelixis licensed cabozantinib to Ipsen for commercialization outside the U.S., Canada, and Japan, and to Takeda for Japan. Both partnerships generate royalty revenues for Exelixis on international net sales of the cabozantinib franchise.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating